Announcement on Holding the 2020 Annual Performance and Cash Dividend Explanation Meeting
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2021-012
Zhejiang Jianfeng Group Co., Ltd.
Announcement
on Convening 2020 Annual Performance and Cash Dividend Explanation Meeting The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
- Meeting Time: May 14, 2021, 14:00-15:00
- Meeting Place: Investors can log on the following website to participate in this briefing online: http://sns.sseinfo.com.
- Meeting Convening Method: Investors of Network Platform
- can send relevant questions to our mailbox by email before 12:00 noon on May 14, 2021: jianfeng20210427@126.com . The Company will answer questions of general concern to investors at the 2020 Annual Results and Cash Dividend Statement.
1. Explanation Meeting Type
Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company") held the 2nd meeting of the 11th Board of Directors on April 24, 2021 to review and approve the "Profit Distribution Plan for 2020". The announcement of the resolution of the meeting was published on April 27, 2021 in the designated information disclosure media and the website of Shanghai Stock Exchange (www.sse.com.cn ).
In accordance with the "Guidelines on Cash Dividends for Listed Companies on the Shanghai Stock Exchange", "Notice on Promoting the Work of Listed Companies to Hold Investor Briefings" and other relevant regulations, in order to enable investors to have a more comprehensive and in-depth understanding of the company's situation, the company Decided to hold a 2020 annual performance and cash dividend briefing to fully communicate with investors on the company's 2020 annual performance and profit distribution. The time and place of the
2. explanation meeting
company will conduct online communication with investors through the "Shanghai e interview" column of the "Shanghai e interaction" network platform (http://sns.sseinfo.com) of Shanghai stock exchange on may 14, 2021 from 14:00 p.m. to 15:00 p.m.
3. Participants
Company Chairman Jiang Xiaomeng, General Manager Yu Jianhong, Chief Financial Officer Lan Xiaolong, and Board Secretary Zhu Jianwei. (If there are special circumstances, the participants may make adjustments)
4. the way investors participate
(I) Investors can send relevant questions to the company's mailbox: jianfeng20210427@126.com by email before 12:00 noon on May 14, 2021. The Company will answer questions of general concern to investors at the 2020 Annual Results and Cash Dividend Statement. (II) investors can register through the internet and log on to the online platform (http://sns.sseinfo.com) from 14:00 p.m. to 15:00 p.m. on may 14, 2021 to attend this briefing online.
5. contact person and consultation method
person in charge and contact information of the investor briefing meeting of listed companies.
Contact: Zhu Jianwei, Yu Guo
Tel: 0579-82320582, 82324699
Fax: 0579-89324699
Email:
jianfeng20210427@126.com
is hereby announced
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
April 30, 2001
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page